| Identification | More | [Name]
TAUROCHENODEOXYCHOLIC ACID SODIUM SALT | [CAS]
6009-98-9 | [Synonyms]
2-([3-ALPHA,7-ALPHA-DIHYDROXY-24-OXO-5-BETA-CHOLAN-24-YL]AMINO)ETHANESULFONIC ACID
2-[(3ALPHA,7ALPHA-DIHYDROXY-24-OXO-5BETA-CHOLAN-24-YL)AMINO]ETHANESULFONIC ACID SODIUM SALT
3ALPHA,7ALPHA-DIHYDROXY-5BETA-CHOLAN-24-OIC ACID N-[2-SULFOETHYL]AMIDE SODIUM SALT
5BETA-CHOLAN-24-OIC ACID N-[2-SULFOETHYL]AMIDE-3ALPHA,7ALPHA-DIOL SODIUM SALT
5BETA-CHOLANIC ACID-3ALPHA,7ALPHA-DIOL-24-N-(2-SULFOETHYL)-AMIDE SODIUM
5-BETA-CHOLANIC ACID-3-ALPHA, 7-ALPHA-DIOL N-(2-SULPHOETHYL)-AMIDE SODIUM SALT
SODIUM TAUROCHENODEOXYCHOLATE
SODIUM TAUROCHENODEOXYCHOLIC ACID
TAUROCHENODEOXYCHOLIC ACID SODIUM
TAUROCHENODEOXYCHOLIC ACID SODIUM SALT
TAUROCHENODESOXYCHOLIC ACID, SODIUM SALT
2-([3α,7α-dihydroxy-24-oxo-5β-cholan-24-yl]amino)ethanesulfonic acid sodium salt
NSC681055
Taurochenodeoxycholic acid sodium salt, 2-([3α,7α-Dihydroxy-24-oxo-5β-cholan-24-yl]amino)ethanesulfonic acid sodium salt, 3α,7α-Dihydroxy-5β-cholan-24-oic acid N-(2-sulfoethyl)amide sodium salt | [Molecular Formula]
C26H44NNaO6S | [MDL Number]
MFCD00036745 | [Molecular Weight]
521.69 | [MOL File]
6009-98-9.mol |
| Hazard Information | Back Directory | [Description]
Taurochenodeoxycholic acid (TCDCA) is a taurine-conjugated form of the primary bile acid chenodeoxycholic acid (CDCA; Item No. 10011286).1 Serum levels of TCDCA increase approximately 5-fold in within two hours and begin to decrease within four hours during an oral lipid tolerance test in humans.2 Serum levels of TCDCA are increased in patients with liver cirrhosis and may serve as a marker of disease progression.3 | [Chemical Properties]
Solid | [Uses]
Labeled Taurochenodeoxycholic Acid, intended for use as an internal standard for the quantification of Taurochenodeoxycholic Acid by GC- or LC-mass spectrometry. | [Uses]
Taurochenodeoxycholic acid sodium salt is a bile acid conjugate and metabolite Taurolithocholic Acid (T009100) with antiinflammatory activity. It has been shown to inhibit hepatocyte apopt osis through suppression of Bid translocation to mitochondria.
| [General Description]
An ionic detergent used for solubilizing lipids and proteins. | [in vivo]
Taurochenodeoxycholic acid (12-Deoxycholyltaurine; TCDCA; 0.05, 0.1g/kg) sodium decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2[2].
Taurochenodeoxycholic acid sodium significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation[3].
Taurochenodeoxycholic acid sodium significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats[4].
| [IC 50]
Microbial Metabolite; Human Endogenous Metabolite | [storage]
Store at -20°C | [References]
[1] HOFMANN A F. The continuing importance of bile acids in liver and intestinal disease.[J]. Archives of internal medicine, 1999, 159 22: 2647-2658. DOI: 10.1001/archinte.159.22.2647
[2] A. SCHMID. Bile Acid Metabolome after an Oral Lipid Tolerance Test by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)[J]. PLoS ONE, 2016, 11 1. DOI: 10.1371/journal.pone.0148869
[3] XIAONING WANG. Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis[J]. Journal of Proteome Research, 2015, 15 4: 1126-1134. DOI: 10.1021/acs.jproteome.5b00217 |
|
|